HSP90 inhibition enhances antimitotic drug-induced mitotic arrest and cell death in preclinical models of non-small cell lung cancer.

HSP90 inhibition enhances antimitotic drug-induced mitotic arrest and cell death in preclinical models of non-small cell lung cancer.

HSP90 inhibitors are currently undergoing clinical evaluation in combination with antimitotic drugs in non-small cell lung cancer (NSCLC), but little is known about the cellular effects of this novel drug combination. Therefore, we investigated the molecular mechanism of action of IPI-504 (retaspimy...

Full description

Bibliographic Details
Main Authors: Brenda C O'Connell, Katie O'Callaghan, Bonnie Tillotson, Mark Douglas, Nafeeza Hafeez, Kip A West, Howard Stern, Janid A Ali, Paul Changelian, Christian C Fritz, Vito J Palombella, Karen McGovern, Jeffery L Kutok
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4277299?pdf=render

Internet

http://europepmc.org/articles/PMC4277299?pdf=render

Similar Items